Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00791856 · ClinicalTrials.gov registry record · Phase 1
Bioequivalence of Testosterone Reduced-size Patch Relative to the Testosterone Reference Patch
A Phase 1 study, sponsored by Warner Chilcott.
- Completed
- Registry status
- Phase 1
- Development phase
- 110
- Enrollment target
NCT00791856 is a Phase 1 study that has completed, run by Warner Chilcott. The registered enrollment target is 110 participants.
The verdict
NCT00791856, a Phase 1 study, has completed, sponsored by Warner Chilcott.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 110 participants
- Enrollment target
Study Summary
This is an open-label, multiple-dose, randomized, two-period crossover bioequivalence study in approximately 110 surgically or naturally postmenopausal women on stable hormone therapy (i.e., estrogen for surgically postmenopausal women or a continuous regimen of estrogen plus progestin for naturally postmenopausal women) restricted to approved oral or transdermal regimens only, or not on concomitant hormone therapy.
Interventions
- DRUG testosterone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2007-07 |
| Est. Completion | 2008-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00791856
The ClinicalTrials.gov registry entry for NCT00791856 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Warner Chilcott, which has 53 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which testosterone is the first listed.
NCT00791856 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00791856 about?
NCT00791856 is a clinical study titled "Bioequivalence of Testosterone Reduced-size Patch Relative to the Testosterone Reference Patch". This is an open-label, multiple-dose, randomized, two-period crossover bioequivalence study in approximately 110 surgically or naturally postmenopausal women on stable hormone therapy (i.e., estrogen for surgically postmenopausal women or a continuous regimen of estrogen plus progestin for naturally...
What is the current status of trial NCT00791856?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 110 participants. The study started on 2007-07. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00791856?
The interventions under investigation include: testosterone (DRUG).
Who is sponsoring clinical trial NCT00791856?
This trial is sponsored by Warner Chilcott, which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.